Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer.

Cristina Guarducci Agostina Nardone Douglas Russo Zsuzsanna Nagy Capucine Heraud Albert Grinshpun Qi Zhang Allegra Freelander Matthew Joseph Leventhal Avery Feit Gabriella Cohen Ariel Feiglin Weihan Liu Francisco Hermida-Prado Nikolas Kesten Wen Ma Carmine De Angelis Antonio Morlando Madison O'Donnell Sergey Naumenko Shixia Huang Quang-De Nguyen Ying Huang Luca Malorni Johann S Bergholz Villafane Jean J Zhao Ernest Fraenkel Elgene Lim Rachel Schiff Geoffrey I Shapiro Rinath M Jeselsohn

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Taken together, these findings support the clinical investigation of selective CDK7 inhibition combined with ET to overcome treatment resistance in ER+ BC. In addition, our study highlights the potential of increased MYC activity and intact P53 as predictors for sensitivity to CDK7 inhibitor-based treatments.

Keyphrases